Indian vaccine maker Bharat Biotech’s nasal Covid-19 vaccine candidate received regulatory approval for mid-stage to late-stage trials, the government’s ministry of science and technology said in a statement on Aug. 13.
The U.S. Food and Drug Administration is expected to announce that the regulatory agency is authorizing the use of a booster shot for the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines in some immunocompromised patients.
Moderna will construct a state-of-the-art manufacturing facility in Canada in order to provide direct access to mRNA vaccines for the Covid-19 pandemic, as well as future viral threats and respiratory viruses.
Moderna Inc. is planning to double the size of an ongoing trial testing the company’s Covid-19 vaccines in children aged 6 months to less than 12 years.
Three new conditions reported by a small number of people after vaccination with Covid-19 shots from Pfizer and Moderna are being studied to assess if they may be possible side effects, Europe’s drugs regulator said on Aug. 11.
Antibody levels are a good predictor for how effective Moderna Inc.’s Covid-19 vaccine is, according to a new study released on Aug. 10, a finding which could help speed up future clinical trials for vaccines against the disease.
The mRNA vaccine from Pfizer and BioNTech may be less effective than Moderna’s against the Delta variant of the coronavirus, according to two reports posted on medRxiv on Aug. 8 ahead of peer review.
Nearly 60 percent of the U.S. population received at least one dose of a Covid-19 vaccine as of the morning of Aug. 9, the U.S. Centers for Disease Control and Prevention said.
The United States administered 351,400,930 doses of Covid-19 vaccines in the country as of the morning of Aug. 8 and distributed 407,561,705 doses, the U.S. Centers for Disease Control and Prevention said.
One out of two Americans were fully vaccinated against Covid-19 as of Aug. 6, according to the U.S. Centers for Disease Control and Prevention.
